Sign in Subscribe
Cancer research

Mutations in Myeloid Transcription Factors and Activated Signaling Genes Predict Chronic Myeloid Leukemia Outcomes

Strategic Insights

— 1 min read

New research from the Princess Margaret Cancer Centre in Toronto, Canada, has shed light on the role of somatic mutations in epigenetic modifier genes and activated signaling/myeloid transcription factors (AS/MTFs) in chronic myeloid leukemia (CML) treatment outcomes. The study found that mutations in AS/MTF genes independently serve as adverse prognostic factors for molecular response, failure-free survival, and progression risk. These findings suggest that mutations in these genes can help identify patients with a potential risk of both treatment failure and progression, and may aid in upfront tyrosine kinase inhibitor (TKI) selection.

Key Takeaways:

  • Research on chronic myeloid leukemia (CML) found that somatic mutations in epigenetic modifier genes and activated signaling/myeloid transcription factors (AS/MTFs) are associated with worse treatment outcomes.
  • Mutations in AS/MTF genes were detected in 57 diagnostic samples (22.4%), whereas 64 mutations were detected in 39 of the follow-up samples (27.9%).
  • Carrying any mutation at initial diagnosis was associated with worse outcomes after TKI therapy, particularly in AS/MTF genes.
  • Patients with these mutations at initial diagnosis and treated with imatinib showed higher risks of treatment failure (hazard ratio, 2.53; 95% confidence interval, 1.13-5.66; P = .0239).
  • The multivariate analysis affirmed that mutations in AS/MTF genes independently serve as adverse prognostic factors for molecular response, failure-free survival, and progression risk.
  • The study also found a nonsignificant trend indicating a heightened risk of progression to advanced disease and worse overall survival.

Statistics:

  • 394 CML samples were sequenced, including 254 samples collected at initial diagnosis and 140 samples taken during follow-up.
  • 57 diagnostic samples (22.4%) and 39 follow-up samples (27.9%) were found to have mutations in AS/MTF genes.
  • 64 mutations were detected in 39 of the follow-up samples (27.9%).
  • The hazard ratio for treatment failure in patients with mutations in AS/MTF genes was 2.53 (95% confidence interval, 1.13-5.66; P = .0239).

Sources:

  • "Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes." Blood Advances, 2024,8(10).
  • American Society of Hematology. https://doi-org.sdpl.idm.oclc.org/10.1182/bloodadvances.2023012127

Read more